Roche to acquire GenMark Diagnostics for $1.8 billion

Roche signed a definitive merger agreement to acquire GenMark Diagnostics for $24.05 per share, totaling approximately $1.8 billion. GenMark's molecular diagnostic tests complement Roche's portfolio.

“The addition of GenMark’s proprietary multiplex technology complements Roche’s diagnostic offering, addressing a broad range of infectious disease testing needs.”roche.com

• 2 sources
• roche.comRoche signs definitive merger agreement with GenMark Diagnostics, Inc., to access novel technology to test for broad range of pathogens with one patient sampleMar 15, 2021
• roche.comRoche signs definitive merger agreement with GenMark Diagnostics, Inc., to access novel technology to test for broad range of pathogens with one patient sampleMar 15, 2021

Summarized from public sources; check the original articles before acting on it.